<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052103</url>
  </required_header>
  <id_info>
    <org_study_id>13261</org_study_id>
    <secondary_id>H8Y-MC-HBCO</secondary_id>
    <nct_id>NCT01052103</nct_id>
  </id_info>
  <brief_title>A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms</brief_title>
  <official_title>A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether LY2140023, when added to standard-of-care
      antipsychotic treatment, will improve negative symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the 16-item Negative Symptoms Assessment (NSA-16)</measure>
    <time_frame>Baseline, 16 or 17 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Baseline, 16 or 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Global Impression Severity Scale (CGI-S)</measure>
    <time_frame>Baseline, 16 or 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB)</measure>
    <time_frame>Baseline, 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in University of California at San Diego Performance-Based Skills Assessment-Brief Version (UPSA-B)</measure>
    <time_frame>Baseline, 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Barnes-Akathisia Scale</measure>
    <time_frame>Baseline, 16 or 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of epileptiform activity in Electroencephalograms (EEGs)</measure>
    <time_frame>Up to 19 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of potentially clinically significant changes in QT intervals Electrocardiograms (ECGs)</measure>
    <time_frame>Up to 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of change in Neurological Examination</measure>
    <time_frame>Up to 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure</measure>
    <time_frame>Baseline, 16 or 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weight</measure>
    <time_frame>Baseline, 16 or 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of potentially clinical significant change in laboratory values</measure>
    <time_frame>Up to 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of potentially clinical significant change of Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Up to 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 17 weeks endpoint in Personal and Social Performance (PSP) Scale</measure>
    <time_frame>Baseline, 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discontinuation</measure>
    <time_frame>Up to 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Simpson Angus Scale</measure>
    <time_frame>Baseline, 16 or 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>Baseline, 16 or 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pulse rate</measure>
    <time_frame>Baseline, 16 or 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from 1 week to 18 weeks endpoint in the Schizophrenia Resource Use Module (S-RUM)</measure>
    <time_frame>1 week, 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 17 weeks endpoint in the EuroQol Questionnaire-5 Dimension (EQ-5D)</measure>
    <time_frame>baseline, 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 17 weeks endpoint in the Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-S)</measure>
    <time_frame>baseline, 17 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>LY2140023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2140023</intervention_name>
    <description>40mg, oral tablets, twice daily: 20 mg in the morning, 20 mg in the evening, for 16 or 17 weeks. The dose may be adjusted to a minimum of 20mg or a maximum of 80mg.</description>
    <arm_group_label>LY2140023</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>U.S. label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)</description>
    <arm_group_label>LY2140023</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Zyprexa</other_name>
    <other_name>LY170053</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of schizophrenia

          -  Patients must have been receiving monotherapy treatment for at least 3 months prior to
             study entry with one of 4 atypical antipsychotic medications (aripiprazole,
             olanzapine, risperidone, quetiapine)

          -  Disease symptoms must meet a certain range as assessed by the clinician

          -  Patients must have evidence of prominent negative symptoms of schizophrenia (i.e.
             blunted affect, emotional withdrawal, or motor retardation)

          -  Patients must be considered reliable, have a level of understanding sufficient to
             perform all tests and examinations required by the protocol, and be willing to perform
             all study procedures

          -  Patients must be able to understand the nature of the study and have given their
             informed consent

        Exclusion Criteria:

          -  Patients who are actively suicidal

          -  Patients who are pregnant or nursing

          -  Patients who have had electroconvulsive therapy (ECT) within 3 months of screening or
             who will have ECT at any time during the study

          -  Patients with uncorrected narrow-angle glaucoma, history of or current seizure
             disorder, uncontrolled diabetes, certain diseases of the liver, renal insufficiency,
             uncontrolled thyroid condition or other serious or unstable illnesses

          -  Patients with Parkinson's disease, psychosis related to dementia or related disorders

          -  Patients with known Human Immunodeficiency Virus positive (HIV+) status
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jerusalem</city>
        <zip>91060</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zamora</city>
        <zip>49021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <disposition_first_submitted>September 18, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>September 18, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 25, 2012</disposition_first_posted>
  <last_update_submitted>September 18, 2012</last_update_submitted>
  <last_update_submitted_qc>September 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

